26-Feb-2020 | Facts and Factors
Facts and Factors have authored “RNAi for the Therapeutics Market by Type (siRNA, miRNA, and shRNA), and By Sales Channel (Direct & Distributor) for Cancer, Ocular Disorder, HBV and Others: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026”. Based on our analysis, the global RNAi for the Therapeutics market in 2019 is approximately USD 674.46 Million and is anticipated to reach around USD 2,493.73 Million by 2026. The anticipated CAGR for the RNAi for the Therapeutics market is around 20.7% from 2020 to 2026.
The RNA interference (RNAi) is a mechanism that prevents gene expression at the phase of conversion or by obstructing the transcription of precise genes. RNAi targets contain RNA from transposons and viruses. RNA interference (RNAi) is a significant way that is utilized in several creatures to control gene expression.
Browse the full “RNAi for the Therapeutics Market by Type (siRNA, miRNA, and shRNA), and By Sales Channel (Direct & Distributor) for Cancer, Ocular Disorder, HBV and Others: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026" report at https://www.fnfresearch.com/rnai-for-the-therapeutics-market-by-type-sirna
The increasing demand for RNAi Therapeutics in cancer therapy helps in fueling the growth of the global RNAi for the Therapeutics market. Moreover, an increasing percentage of the cancer population across the world is also one of the key driving factors for the growth of the market. Furthermore, government policies and increasing funding for research and development is the major driving factor for the growth of the market. Lack of skilled professionals in this sector affecting the growth of the market. Nonetheless, ongoing research and technology and trend will bring huge opportunities within the forecast period.
Based on the product, the market of RNAi for Therapeutics is classified as siRNA, miRNA, and shRNA. siRNA accounts for the largest market share in terms of revenue in the RNAi for the Therapeutics market over the forecast period. The siRNA segment is followed by the miRNA segment in terms of revenue share. The miRNA type segment is anticipated to account for around 11.9% of the global RNAi for the Therapeutics market in the year 2019.
On the basis of application, the global market of RNAi for Therapeutics is categorized into Cancer, Ocular disorder, HBV and Others. The cancer segment accounted for the largest share in terms of revenue. The cancer segment generates USD 326.42 million in the year 2019. World manufacturers are showing keen interest in designing product by keeping cancer diseases as concerned.
On the basis of region the global market of RNAi for Therapeutics is classified into, Americas, Asia Pacific, Europe, Middle East & Africa. In 2019, the North America region is the most attractive and largest consumer in this market. The U.S. is the major driving country in the Americas region.
Major key market players are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Quark Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics and Others
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 27 Million |
Projected Market Size in 2026 |
USD 70 million |
CAGR Growth Rate |
18.91% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Quark Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics, and Others |
Key Segment |
By Type, By Application, By Distribution, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
This report segments the global RNAi for Therapeutics market as follows:
Global RNAi for Therapeutics Market: Type Analysis
Global RNAi for Therapeutics Market: Application Analysis
- Cancer
- Ocular Disorder
- HBV
- Others
Global RNAi for TherapeuticsMarket: Sales Channel Analysis
- Direct Channel
- Distributor Channel
Global RNAi for TherapeuticsMarket: Regional Analysis
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-East Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- The Middle-East and Africa
- GCC Countries
- South Africa
- Rest of Middle-East Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
